Bambusa Therapeutics, Inc. is left out of our screens and market counts tonight, which cover US stocks priced at $5 or more and trading at least $1 million a day on average. Its read below still updates after every close.
Bambusa Therapeutics, Inc.
Every stock that changed stage on Oct 30, 2026 →
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Is BBTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BBTX among Biotechnology
All 237 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | IOVA | Stage 2 · wk 20 | 99 | −37.6% |
| 2 | SLS | Stage 3 · wk 6 | 99 | −23.7% |
| 3 | MRNA | Stage 2 · wk 19 | 99 | +12.4% |
| 4 | SYRE | Stage 3 · wk 6 | 99 | +7.1% |
| 5 | TWST | Stage 2 · wk 41 | 99 | −31.6% |
| 6 | KOD | Stage 2 · wk 5 | 99 | +5.4% |
| 7 | ERAS | Stage 3 · wk 6 | 99 | −0.5% |
| 8 | CLYM | Stage 3 · wk 5 | 99 | −11.8% |
Bambusa Therapeutics: quick answers
Which sector and industry is Bambusa Therapeutics in?
Bambusa Therapeutics is in the Biotechnology industry, part of the Health Care sector. 187 stocks in Health Care are in Stage 2, 37.4% of the sector. See the Stage 2 stocks in Biotechnology
About this companyHealth Care· Biotechnology
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-11-03. Past data patterns are not indicative of future results. This page is a data analytics tool only.